| 中文名称: | SKA-31 | ||||
|---|---|---|---|---|---|
| 英文名称: | SKA-31 | ||||
| 别名: | SKA-31 SKA-31 | ||||
| CAS No: | 40172-65-4 | 分子式: | C11H8N2S | 分子量: | 200.26 |
| CAS No: | 40172-65-4 | ||||
| 分子式: | C11H8N2S | ||||
| 分子量: | 200.26 | ||||
| EINEC: | 6278 | ||||
| EINEC: | 6278 | ||||
基本信息
|
产品编号： |
S10975 |
||||
|
产品名称： |
SKA-31 |
||||
|
CAS: |
40172-65-4 |
储存条件 |
粉末 |
2-8℃ |
四年 |
|
分子式： |
溶于液体 |
-80℃ |
6个月 |
||
|
分子量： |
200.26 |
-20℃ |
1个月 |
||
|
化学名： |
SKA 31;SKA31;Naphtho[1,2-d]thiazol-2-ylamine;2-Amino-beta-naphthothiazole;2-Aminonaphthiazole |
||||
|
Solubility (25°C)： |
|||||
|
体外:
|
DMSO |
|
|||
|
Ethanol |
'mg/mL |
||||
|
Water |
|
||||
|
体内(现配现用): |
|
||||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
制备储备液
|
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
|
1mM |
4.9935mL |
24.9675mL |
49.9351mL |
|
5mM |
0.9987mL |
4.9935mL |
9.9870mL |
|
10mM |
0.4994mL |
2.4968mL |
4.9935mL |
生物活性
|
产品描述 |
一种钾离子通道(potassiumchannel)激活剂，能增强内皮源性超极化因子反应，降低血压。 |
|
|
靶点 |
EC50:2.9μM (KCa2.1),1.9μM (KCa2.2),2.9μM (KCa2.3),260nM (KCa3.1) |
|
|
体外研究 |
SKA-31 activates KCa2/3 channels more potently than PK 26124,and is more selective over other Ion channels.SKA-31 reduces cell viability with IC50s of 5.3μM,46.9μM in HCT-116 cells and HCT-8 cells,respectively.SKA-31 (5.3μM;0-96 hours) reduces HCT-116 cells proliferation when added at time zero at 5.3μM.SKA-31 triggers apoptosis in HCT-116 cells at 5μM,and the effect is smaller in HCT-8 cells at 45μM.SKA-31 increases the percentage of cells in G0/G1 phase in HCT-116 and HCT-8 cell lines at 5μM and 45μM,respectively.SKA-31 further activates Caspase 3 and reduces Akt phosphorylation induced by CDDP.SKA-31 has a synergic effect with CDDP also on the inhibition of HCT-116 cell proliferation. Cell Viability Assay |
|
|
Cell Line: |
HCT-116 cells,HCT-8 cells |
|
|
Incubation Time: |
24 hours |
|
|
Result: |
Reduced cell viability with IC50s of 5.3μM, 46.9μM in HCT-116 and HCT-8,respectively. |
|
|
Cell Proliferation Assay |
||
|
Cell Line: |
HCT-116 cells |
|
|
Concentration: |
5.3μM |
|
|
Incubation Time: |
0-96 hours |
|
|
Result: |
Reduced HCT-116 cells proliferation when added at time zero at IC50S value. |
|
|
Apoptosis Analysis |
||
|
Cell Line: |
HCT-116 cells,HCT-8 cells |
|
|
Concentration: |
5μM (HCT-116 cells),45μM (HCT-8 cells) |
|
|
Incubation Time: |
24 hours |
|
|
Result: |
Triggered apoptosis in HCT-116 cells, and the effect was smaller in HCT-8 cells. |
|
|
Cell Cycle Analysis |
||
|
Cell Line: |
HCT-116 cells,HCT-8 cells |
|
|
Concentration: |
5μM (HCT-116),45μM (HCT-8) |
|
|
Incubation Time: |
24 hours |
|
|
Result: |
Increased the percentage of cells in G0/G1 phase in HCT-116 and HCT-8 cell lines. |
|
|
Western Blot Analysis |
||
|
Cell Line: |
HCT-116 cells |
|
|
Incubation Time: |
24 hours |
|
|
Result: |
Further activated Caspase 3 and reduced Akt phosphorylation when co-treatment with CDDP in HCT-116 cells. |
|
|
体内研究 |
SKA-31 is not acutely toxic and has good pharmacokinetic properties.SKA-31 potentiates native KCa3.1 and KCa2.3 in murine carotid endothelium with EC50 values of 225nM and 1.6μM for KCa3.1 and KCa2.3,respectively.SKA-31 stimulates KCa3.1 and KCa2.3 in vascular endothelial cells and increases acetylcholine-induced endothelium-derived hyperpolarizing factor (EDHF) -mediated vasodilation.SKA-31 potentiates EDHF-type vasodilations and lowers blood pressure in mice.Injections of SKA-31 (1-30mg/kg;i.p.) lower MAP over 24 hours in normotensive wild-type mice but not in KCa3.1(-/-) mice (-/-). |
|
|
Animal Model: |
16-25 weeks mice |
|
|
Dosage: |
1mg/kg,10mg/kg,and 30mg/kg |
|
|
Administration: |
Intraperitoneal injection |
|
|
Result: |
Lower MAP over 24 hours in normotensive wild-type mice but not in KCa3.1(-/-)mice (-/-). |
|
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
